New research suggests that individuals who discontinue popular GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle programs.
Findings released in a leading health publication points out that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these treatments need to be aware of the risk of rapid rebound weight gain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
That rate of regain implies a return to original mass within about 18 months.
Comparing Treatments
The research, which examined 37 of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with older methods.
Researchers emphasize that individuals who lose weight through dieting usually experience a more gradual weight regain—around 100 grams monthly—once they finish.
Understanding the Quick Rebound
Nutrition scientists propose the mechanism of the injections accounts for the heightened regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels far above than the body's typical production may cause the body to produce less of its own natural hormone, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication results in hunger is uncontrolled, making overeating much more probable."
A Lifelong Condition?
Medical guidelines recommend the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, considering the high risk of relapse, the therapy is often long-term.
This perspective is supported by drug manufacturers, who state that the findings "underscore the chronic nature of excess weight," comparing it to managing conditions like hypertension.
User Testimonies
Users who have discontinued the medication explain a intense resurgence of cravings.
"I experienced something that goes on and you're instantly ravenous," described a patient.
The struggle is worsened if users have not established permanent dietary or behavioural changes during therapy.
Significant Adoption
Figures suggest that millions of people in the UK have used weight-loss jabs in the past year, with demand being substantial.
- Adoption is higher among females than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, researchers caution that while these medications are potent tools for weight loss, they are not a standalone solution and maintained weight loss likely depends on integrated behavioural support.
